Skip to main content
Premium Trial:

Request an Annual Quote

Cenix to Help Regulus Develop Targets for miRNA-Based Drugs

NEW YORK (GenomeWeb News) – Cenix BioScience said today that it has agreed to help Regulus Therapeutics develop its miRNA modulators for immunology and inflammation therapeutics. 
Under the research agreement, Cenix said it will use multi-parametric assays to screen Regulus’ libraries of synthetic miRNA modulators for novel molecules that could be used to develop new therapeutics. Specifically, Cenix said that it will apply its small RNA-based gene silencing technology with high-content phenotypic analyses in cultured human cells.
Regulus is a California-based company that was founded in 2007 as a joint effort between Alnylam Pharmaceuticals and Isis Pharmaceuticals.
Cenix offers research and consulting services using human and rodent cell models to discover, validate, and analyze new drug targets for a variety of diseases including atherosclerosis, diabetes, obesity, malaria, and others.

Financial terms of the agreement were not released.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.